Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sudeep PharmaBOM:544619 +4.41%21 Receivables Turnover is 0.70 as of Jun. 2026. GuruFocus rates BOM:544619 with a GF Score™ of 21/100. The stock has 8 warning signs investors should review. Among 948 Drug Manufacturers companies, Sudeep Pharma ranks worse than 87.87% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Sudeep Pharma's Revenue for the
three
months ended in Jun. 2026 was ₹1,583 Mil. Sudeep Pharma's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹2,275 Mil.
Hence, Sudeep Pharma's Receivables Turnover for the
three
months ended in Jun. 2026 was 0.70.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Sudeep Pharma Receivables Turnover Related Terms
Sudeep Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Sudeep Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544619 vs ZTS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sudeep Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sudeep Pharma Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sudeep Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Sudeep Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sudeep Pharma (BOM:544619) has a Receivables Turnover of 0.70 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sudeep Pharma and its competitors. According to the industry distribution chart, Sudeep Pharma ranks #833 out of 948 companies in the Drug Manufacturers industry, placing it in the top 87.9%.
Is Sudeep Pharma's Receivables Turnover too high?
Sudeep Pharma's current Receivables Turnover is 0.70. The Drug Manufacturers industry median Receivables Turnover is 5.07. Sudeep Pharma's value of 0.70 is 86.2% below this industry median. Based on the distribution chart, Sudeep Pharma ranks #833 out of 948 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sudeep Pharma has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Sudeep Pharma's Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sudeep Pharma ranks #833 out of 948 companies for Receivables Turnover. This places Sudeep Pharma in the lower half of its industry. The industry median Receivables Turnover is 5.07. Sudeep Pharma's value of 0.70 is 86.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sudeep Pharma's current Receivables Turnover of 0.70 is 86.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sudeep Pharma and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sudeep Pharma's current Receivables Turnover is 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudeep Pharma stock overvalued right now?
Sudeep Pharma (BOM:544619) has a current Receivables Turnover of 0.70. The current Receivables Turnover is 0.70 and 86.2% below the Drug Manufacturers industry median of 5.07. Sudeep Pharma's overall GF Score™ is 21/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Sudeep Pharma (BOM:544619), the current Receivables Turnover is 0.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sudeep Pharma Ltd is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries and is dedicated to contributing to the healthcare ecosystem. The company operates in two business verticals: Pharmaceutical, food, and nutrition. It focuses on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries and Specialty ingredients: It pertains manufacturing of specialty ingredients using advance technology solutions. The maximum revenue is generated from the Pharmaceutical, food, and nutrition segment. Geographically, it has presence in the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
21GF Score
Get the complete analysis for BOM:544619
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544619 has been successfully added to your 
